MNX1 and acute myeloid leukemia: Of these compounds, only 5-aza-2’-deoxycitidine (decitabine, DAC), a DNA methyltransferase (DNMT) inhibitor in clinical use in myelodysplastic syndrome and other hematological malignancies including AML [1], significantly suppressed MNX1 (Fig. 1B).